Author(s): Larsen RH, Borrebaek J, Dahle J, Melhus KB, Krogh C,
Abstract Share this page
Abstract In this study, the feasibility of constructing radioimmunoconjugates by using the novel therapeutic candidate alpha-emitter, (227)Th, was evaluated. By use of the bifunctional chelator, p-SCN-benzyl-DOTA, (227)Th was conjugated to the two monoclonal antibodies, rituximab and trastuzumab. Their stability in 80\% fetal bovine serum at 37 degrees C was measured. The immunoreactive fractions were determined by using CD20- and HER/2-positive cells, respectively. The overall labeling yield spanned from 6\% to 17\%. The radioimmunoconjugates demonstrated a relevant stability in serum and showed appropriate antigen-binding abilities.
This article was published in Cancer Biother Radiopharm
and referenced in Anthropology